Analytical Data
-
Gene name
HLA-A*02:01&B2M&Survivin(TLPPAWQPFL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & Survivin (TLPPAWQPFL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&TLPPAWQPFL
-
Molecular Weight
40-43 kDa and 12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*02:01, β2-microglobulin (B2M), and the tumor-associated peptide Survivin (TLPPAWQPFL) monomer recombinant protein is crucial in the field of cancer immunotherapy. HLA-A*02:01 is one of the most common human leukocyte antigen alleles, playing a vital role in the presentation of tumor antigens to cytotoxic T lymphocytes. Survivin, an inhibitor of apoptosis protein, is overexpressed in many tumors and presents a promising target for immunotherapy due to its limited expression in normal tissues. By creating a recombinant protein complex of HLA-A*02:01, B2M, and Survivin, researchers aim to enhance the anti-tumor immune response. This approach facilitates the understanding of how the immune system can recognize and attack cancer cells presenting the Survivin peptide. Such studies can lead to the development of effective vaccines and targeted therapies that harness the patient’s immune system, potentially improving outcomes in various cancers. Overall, the recombinant protein serves as a valuable tool for dissecting immune recognition mechanisms and advancing personalized cancer treatment strategies.
